Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression
Barbara A Fox1, Kiah L Sanders1, David J Bzik1
1Department of Microbiology and Immunology; Geisel School of Medicine at Dartmouth; Lebanon, NH USA.
Oncoimmunology
|December 20, 2013
Abstract:
We examined the efficacy of using attenuated non-replicating Toxoplasma gondii uracil auxotrophs that can be safely delivered as anticancer immunotherapeutics. This strategy exerted remarkable therapeutic activity in murine models of melanoma and ovarian carcinoma, and holds broad potential for the development of novel, highly effective anticancer vaccines.


